Tumor-associated EVs extensively circulate in biological fluids of cancer patients, and it is conceivable that high levels of blood-derived CD133+ and EPCAM+ EVs in patients with mCRC might be related with an increased secretion of these EV subtypes by cancer cells. Here, PROM1 is linked to cancer.